Mazdutide
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Innovent · Phase 1/2 · Active, not recruiting · Enrollment 98
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.